We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Valneva SE (VLA) Common Shares EUR0.15

Sell:€1.90 Buy:€1.97 Change: €0.08 (3.99%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:€1.90
Buy:€1.97
Change: €0.08 (3.99%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:€1.90
Buy:€1.97
Change: €0.08 (3.99%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

Contact details

Address:
6 rue Alain Bombard
SAINT-HERBLAIN
44800
France
Telephone:
+33 (2) 28073710
Website:
https://valneva.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
VLA
ISIN:
FR0004056851
Market cap:
€325.69 million
Shares in issue:
139.15 million
Sector:
Biotechnology
Exchange:
Euronext Paris
Country:
France
Currency:
Euro
Indices:
n/a

Key personnel

  • Thomas Lingelbach
    President, Chief Executive Officer, Director
  • Peter Buehler
    Chief Financial Officer
  • Vincent Dequenne
    Chief Operating Officer
  • Petra Pesendorfer
    Chief People Officer
  • Hanneke Schuitemaker
    Chief Scientific Officer
  • Kendra Wergin
    General Counsel, Corporate Secretary
  • Franck Grimaud
    Chief Business Officer
  • Juan Jaramillo
    Chief Medical Officer
  • Dipal Patel
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.